SLC5A2 and heart failure: Surprisingly, after developing HFpEF requiring the addition of guidelines-adjusted therapy with sodium-glucose cotransporter-2 inhibitors (SGLT2i), besides a significant improvement of signs and symptoms characterizing heart failure, we obtained, first, a reduction and, subsequently, the disappearance of VA.